Format

Send to

Choose Destination
J Neurooncol. 2015 Sep;124(2):325-32. doi: 10.1007/s11060-015-1844-8. Epub 2015 Jun 13.

Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model.

Author information

1
Department of Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany. klausmueller1978@googlemail.com.
2
Department of Radiation Oncology, Hospital Chemnitz, Bürgerstraße 2, 09113, Chemnitz, Germany. klausmueller1978@googlemail.com.
3
Department of Radiation Oncology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
4
Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany.
5
Department of Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany.
6
Laboratory of Experimental Immunology, Catholic University Leuven, Leuven, Belgium.
7
Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center Göttingen, Göttingen, Germany.
8
Department of Radiation Oncology (MAASTRO), GROW (School for Oncology & Developmental Biology), University of Maastricht Medical Center, Maastricht, The Netherlands.
9
Division of Pediatric Oncology, Hematology and Hemostaseology, Department of Woman's and Children's Health, University Hospital Leipzig, Leipzig, Germany.
10
Department of Radiation Oncology, Medical Faculty, Heinrich Heine University of Düsseldorf, Düsseldorf, Germany.
11
Department of Radiation Oncology, Hospital Chemnitz, Bürgerstraße 2, 09113, Chemnitz, Germany.
12
Departments of Neurology and Haematology/Oncology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
13
Clinical Cooperation Unit Neurooncology, Department of Radiation Oncology, MediClin Robert Janker Clinic & University of Bonn Medical Center, Bonn, Germany.

Abstract

We aimed to compare two different salvage treatment strategies for relapsed high-grade glioma (HGG) patients by means of a new prognostic model. A simplified version of the so-called HGG-Immuno RPA model estimates the prognosis of relapsed HGG patients and distinguishes three different prognostic classes (I = good, II = intermediate, III = poor). The model has been constructed with a cohort of 117 patients whose salvage treatment consisted of re-operation followed by dendritic cell vaccination (ReOP + DCV). However, using only the predictors histology, age and performance status, the simplified HGG-Immuno RPA model is basically independent from treatment. In the present study we applied the simplified model to the cohort used to construct the original HGG-Immuno RPA model and another cohort of 165 patients who underwent re-irradiation (ReRT) at relapse. Then, we compared the outcomes achieved by the two different salvage treatments in each prognostic class. The model predicted good, intermediate and poor prognosis for 11, 31 and 75 patients of the ReOP + DCV cohort and for 20, 39 and 106 patients of the ReRT cohort, respectively. Neither of the two strategies was superior to the other. In the groups with good, intermediate and poor prognosis 12-months survival rates were 73, 59 and 25 % after ReOP + DCV and 72, 36 and 23 % after ReRT, respectively. Being easy to handle and independent from treatment, the aforementioned model is useful for therapeutic decisions. ReRT and ReOP + DVC seem to be equally effective. The choice of salvage treatment should be based on the expected side effects.

KEYWORDS:

Dendritic cell vaccination; Prognosis; Prognostic model; Re-irradiation; Recurrent glioblastoma; Relapsed high-grade gliomas; Salvage treatment

PMID:
26070556
DOI:
10.1007/s11060-015-1844-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center